Monday, March 23, 2026

Sandoz launches azelastine/fluticasone nasal spray in Germany and Switzerland

Sandoz has introduced a fixed-dose combination nasal spray containing azelastine and fluticasone in Germany and Switzerland. The company frames the launch as an additional treatment option for patients managing allergy symptoms.

In a statement, Christophe Delenta, President Europe at Sandoz, highlighted the impact seasonal allergies can have on sleep, concentration, productivity and quality of life, and said the rollout is intended to improve access ahead of the 2026 allergy season.

Indications and age groups

In Germany, the azelastine/fluticasone nasal spray is positioned as an over-the-counter option for relieving symptoms of moderate to severe seasonal allergic rhinitis in adults.

In Switzerland, it is approved for seasonal allergic rhinitis and rhino conjunctivitis in patients aged six years and older. It is also approved for moderate to severe perennial allergic rhinitis and rhino conjunctivitis in patients aged 12 years and older.

Market context and reference product

Sandoz cites allergic rhinitis prevalence of around 15 to 20% of the Swiss population, and up to 15 million affected people in Germany. The company refers to Dymista®, a registered trademark of Viatris, as the reference medicine and positions its product as an alternative.

Portfolio positioning

For Germany, Sandoz points to using the established Lorano® brand in the OTC allergy segment and links the launch to Hexal’s positioning in OTC allergy care. In Switzerland, Sandoz says the nasal spray strengthens its antihistaminic portfolio.

Beyond allergy care, Sandoz also describes the launch as part of its broader generics strategy and references an estimated USD ~340 billion loss-of-exclusivity opportunity over the next 10 years.